Karyopharm adds Dr. Zhen Su as independent director; board expands to nine

Karyopharm Therapeutics Inc.

Board increased to nine members; Dr. Su elected as Class III director, term through 2025 annual meeting.
Dr. Su receives option for 68,000 shares at $1.28 (closing price on grant date), vesting over three years.
Cash retainer of $50,000 for board service plus $10,000 for committee, prorated from effective date.
Standard indemnification agreement and no related-party transactions requiring disclosure.
Appointed to Commercialization and Portfolio Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Zhen Su

Independent Director

KPTI · Karyopharm Therapeutics Inc.

Effective: 2023-08-31
Filed: September 1, 2023, 7:59 PM ET

elected Zhen Su, M.D., M.B.A, as an independent director of the Company to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Zhen Su was elected as Independent Director at Karyopharm Therapeutics Inc..

Action: elected
Role: Independent Director

Exact text from the filing

elected Zhen Su, M.D., M.B.A, as an independent director of the Company to fill the newly created vacancy.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-226903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.